Published in Cancer Immunol Immunother on November 23, 2010
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. Clin Dev Immunol (2011) 0.78
The Effect of MicroRNA-375 Overexpression, an Inhibitor of Helicobacter pylori-Induced Carcinogenesis, on lncRNA SOX2OT. Jundishapur J Microbiol (2016) 0.75
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell (2008) 7.69
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature (2009) 6.85
A fresh look at iPS cells. Cell (2009) 5.73
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell (2007) 5.29
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev (2009) 4.69
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell (2003) 4.50
From stem cells to neurons and glia: a Soxist's view of neural development. Trends Neurosci (2005) 3.07
Stem cells: The promises and perils of p53. Nature (2009) 3.01
Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells (2009) 2.48
Features of responding T cells in cancer and chronic infection. Curr Opin Immunol (2010) 2.42
Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells (2006) 2.07
Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A (2000) 2.02
OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol (2004) 1.99
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell (2007) 1.87
Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun (2009) 1.84
T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A (2002) 1.74
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Oct4 expression revisited: potential pitfalls for data misinterpretation in stem cell research. Biol Chem (2008) 1.72
Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69
Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS One (2009) 1.69
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer (2007) 1.67
Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A (2005) 1.56
"Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol (2008) 1.53
SOX-partner code for cell specification: Regulatory target selection and underlying molecular mechanisms. Int J Biochem Cell Biol (2009) 1.46
Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med (2003) 1.44
Human embryonic stem cells are prone to generate primitive, undifferentiated tumors in engrafted human fetal tissues in severe combined immunodeficient mice. Stem Cells Dev (2007) 1.43
SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle (2010) 1.23
Expression of pax6 and sox2 in adult olfactory epithelium. J Comp Neurol (2010) 1.16
The transcription factor Sox2 is required for osteoblast self-renewal. Cell Death Differ (2010) 1.16
Neural stem cells in the developing and adult brains. J Cell Physiol (2009) 1.11
p53: a potential target antigen for immunotherapy of cancer. Ann N Y Acad Sci (2000) 1.08
An argument against a role for Oct4 in somatic stem cells. Cell Stem Cell (2007) 1.07
Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A (2010) 1.06
Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells (2009) 1.03
Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene (2002) 1.03
Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway. Am J Surg Pathol (2008) 1.01
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood (2009) 1.00
Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. Cancer Res (2008) 0.99
Immunity to stemness genes in human cancer. Curr Opin Immunol (2010) 0.89
Expression of Sox1, Sox2 and Sox9 is maintained in adult human cerebellar cortex. Neurosci Lett (2008) 0.89
Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer (2010) 0.86
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med (2003) 2.48
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood (2006) 2.36
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood (2012) 1.94
Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol (2011) 0.99
Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgammaRs on human dendritic cells. J Immunother (2008) 0.93
Immunity to stemness genes in human cancer. Curr Opin Immunol (2010) 0.89
Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. Blood (2012) 0.89
Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia. Sci Transl Med (2013) 0.86
Vaccines targeting cancer stem cells: are they within reach? Cancer J (2011) 0.81
Role of chaperones and FcgammaR in immunogenic death. Curr Opin Immunol (2008) 0.79
Central and overlapping role of Cathepsin B and inflammasome adaptor ASC in antigen presenting function of human dendritic cells. Hum Immunol (2012) 0.77
ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. J Clin Invest (2016) 0.76